Polymer-Encapsulated PC-12 Cells Demonstrate High-Affinity Uptake of Dopamine in Vitro and 18F-DOPA Uptake and Metabolism after Intracerebral Implantation in Nonhuman Primates
Open Access
- 1 September 1997
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 6 (5) , 469-477
- https://doi.org/10.1177/096368979700600506
Abstract
Intracranial implantation of polymer-encapsulated PC-12 cells has been shown to improve motor behavioral performance in animal models of Parkinson's disease. The purpose of this blinded study was to examine whether such improvement is associated with the active uptake and metabolism of dopamine precursors by intracerebrally implanted polymer-encapsulated PC-12 cells. In an in vitro experiment we demonstrate that 3H-dopamine uptake by PC-12 cells was 108 fmol/min × 106 cells, and that this uptake can be specifically blocked 88% by the addition of 10 nM of nomifensine. In the in vivo experiments, polymer-encapsulated PC-12 cells were implanted in four MPTP-treated monkeys into the left deep parietal white matter (R1) or left striatum (R2-4). A fifth MPTP-treated monkey (R5) served as a control and received left striatal implants of empty capsules. 18F-Dopa Positron Emission Tomography (PET) imaging was performed on each monkey before and after implantation surgery by blinded investigators. PET images obtained 5-13 wk after implantation demonstrated well delineated focal areas of high 18F-dopa uptake in R1, R2, and R4. The focal area of high 18F-dopa uptake in R1 precisely coregistered on a brain magnetic resonance image to the site of implantation. R3 (in whom the polymer-encapsulated PC-12 cells demonstrated poor cell survival upon explantation) and R5 (empty capsules) failed to demonstrate any area of increased 18F-dopa uptake in their PET images. Histological examination of the host brain revealed no sprouting of dopaminergic nerve terminals around the implantation sites of the polymer-encapsulated PC-12 cells. These results indicate that the previously noted behavioral improvement after intrastriatal implantation of polymer encapsulated PC-12 cells is at least in part due to their highly specific uptake and metabolism of dopamine precursors. Furthermore, these data suggest that polymer-encapsulated PC-12 cells can store, reuptake, and functionally replenish dopamine and therefore, may be an effective treatment for Parkinson's disease.Keywords
This publication has 28 references indexed in Scilit:
- Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's diseaseAnnals of Neurology, 1995
- The dopamine transporter: immunochemical characterization and localization in brainJournal of Neuroscience, 1995
- Functional Recovery in Hemiparkinsonian Primates Transplanted with Polymer-Encapsulated PC12 CellsExperimental Neurology, 1994
- A novel approach to neural transplantation in Parkinson's disease: Use of polymer-encapsulated cell therapyNeuroscience & Biobehavioral Reviews, 1992
- Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinson's diseaseExperimental Neurology, 1992
- Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months after Transplantation for Parkinson's DiseaseNew England Journal of Medicine, 1992
- Transplantation of Polymer Encapsulated Neurotransmitter Secreting Cells: Effect of the Encapsulation TechniqueJournal of Biomechanical Engineering, 1991
- Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell lineExperimental Neurology, 1991
- Macroencapsulation of dopamine-secreting cells by coextrusion with an organic polymer solutionBiomaterials, 1991
- Chapter 81 Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's diseasePublished by Elsevier ,1990